Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease

Table 1 Baseline characteristics of the total 301 study participants, n (%)

Variables	Median (interquartile range)1
Sex
Male	177 (58.8)
Female	124 (41.2)
Age (years)	52 (42-59)
Body mass index (kg/m2)	26.4 (24.5-28.4)
Aspartate aminotransferase (U/L)	30 (22-43)
Alanine aminotransferase (U/L)	40 (25-70.5)
Low density lipoprotein-cholesterol (mmol/L)	3.2 (2.5-4.2)
Triglycerides (mmol/L)	2.3 (1.7-3.5)
Total cholesterol (mmol/L)	5.4 (4.6-6.2)
Gamma glutamyl transferase (U/L)	68 (37.5-120.5)
White blood cell (109/L)	8 (6.9-9.4)
Hemoglobin (g/L)	14.6 (13.5-15.7)
Platelet count (109/L)	261 (224.5-300.5)
Hemoglobin A1c (National Glycohemoglobin Standardization Program)	5.9 (5.6-6.7)
Glucose (mmol/L)	6.2 (5.6-7.5)
Fasting plasma glucose (mg/Dl)	111.9 (101.4-134.3)
Estimated glomerular filtration rate (mL/min/1.73 m2)	100 (89-108)
FibroScan (kPa)	7.7 (6.2-9.4)
Mac-2 binding protein glycosylation isomer level (cut-off index)	0.67 (0.5-0.9)
Aspartate aminotransferase-to-platelet ratio index	0.3 (0.2-0.4)
Fibrosis-4 Index	0.9 (0.6-1.3)
Controlled attenuation parameter	301 (274-327.5)
Fibrosis stage
F0-1	90 (29.9)
F2-3	168 (55.8)
F4	43 (14.3)
Comorbidity
Obesity	41 (13.6)
Diabetes	83 (27.6)

¹Unless otherwise indicated.